ICS 2016
Open Discussion Session 7 Open Discussion ePosters 90 Subgroup analyses of triple therapy with tamsulosin, dutasteride, and imidafenacin for benign prostatic hyperplasia patients with overactive bladder symptoms refractory to tamsulosin (24-week randomized comparative study: DIrecT Study)
ICS 2015
Podium Short Oral Session 14 Male Lower Urinary Tract Dysfunction 209 A prospective, six-year followup of silodosin monotherapy for the treatment of LUTS/BPH: what are the factors for continuation or withdrawal?
ICS 2014
Open Discussion Poster Session 12 Nocturia 151 The efficacy of alpha1A-adrenoceptor antagonists (silodosin and tamsulosin) for the treatment of nocturia with or without NP using frequency-volume chart
Open Discussion Poster Session 37 Pharmacology 565 The efficacy and safety of flexible dose imidafenacin (0.2mg or 0.4mg), for the treatment of overactive bladder and nocturia
Open Discussion Poster Session 37 Pharmacology 574 The effects of tolterodine and 5-hydroxymethyl tolterodine (5HMT) on carbachol-induced contraction in human bladder smooth muscles in normal state and in detrusor overactivity associated with benign prostatic hyperplasia
ICS 2013
Non Discussion Abstract Session 35 Read By Title 701 The effect of L-NG-Nitroarginine Methyl Ester (L-NAME) on relaxation induced by Y 27632, a Rho-kinase inhibitor, in the porcine urinary bladder with intact urothelium
ICS 2012
Non Discussion Poster Session 31 313 Long-Term Efficacy of Silodosin for the Treatment of Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Hyperplasia
ICS 2011
Non Discussion Poster Session 29 290 Comparison of the effects of silodosin and tamsulosin for the treatment of benign prostatic hyperplasia
Non Discussion Abstract Session 31 Read by Title 778 The effects of Pilocarpine, an M3-muscarinic receptor agonist, on contraction of the porcine urinary bladder in vitro
ICS 2009
Non Discussion Poster Session 32 312 Comparison of the efficacy, safety, and tolerability of solifenacin and propiverine for the treatment of overactive bladder
Non Discussion Poster Session 32 330 Efficacy of tolterodine ER for the treatment of neurogenic detrusor overactivity or low compliance bladder – assessment by urodynamic study
Non Discussion Poster Session 32 506 Effects of fasudil, a Rho-kinase inhibitor, for contraction of the pig bladder tissues with or without urothelium
ICS 2008
Podium Session 14 Basic Science 115 Expression of RhoA mRNA and activated RhoA in urothelium and smooth muscle, and effects of a Rho-kinase inhibitor on contraction of the porcine urinary bladder
Non Discussion Poster Session 19 411 The effects of solifenacin on carbachol-induced contraction in human bladder smooth muscles in normal state and in detrusor overactivity associated with benign prostatic hyperplasia
ICS 2007
Non Discussion Abstract Session 19 Read By Title 370 Urodynamic effects of silodosin, a new alpha1A-adrenoceptor selective antagonist, for the treatment of benign prostatic hyperplasia
Non Discussion Abstract Session 19 Read By Title 371 Nocturia in male adults: comparison between patients with BPE and those without BPE
Non Discussion Abstract Session 19 Read By Title 382 The efficacies of interferential therapy for the treatment of urinary incontinence and storage dysfunction refractory to the conventional conservative treatments
Professor Tomonori Yamanishi received his undergraduate and medical degrees from Chiba University School of Medicine in 1982. He served as an assistant professor in the Department of Urology at Chiba University from 1989 to 1997, and then a lecturer until 2001. He worked in the Department of Urology and the Department of Biomedical Science at University of Sheffield, UK from 1998-2001. After completing his studies at University of Sheffield, he returned to Japan in 2001 and worked in the Urology Department at Dokkyo Medical University as an associate professor. He is working as a Professor of Urology, Dokkyo Medical University from 2009, and also a Chief of Continence Center, Dokkyo Medical University in 2011.
Prof Tomonori Yamanishi declared on the Sunday 30th March 2014 that they had the following existing or known future financial relationships or affiliations:
Pfizer
VOLUNTARY (EXPIRED)